Literature DB >> 27774920

Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study.

Hélène Blasco1, Guillaume Garcon2, Franck Patin1, Charlotte Veyrat-Durebex1, Judith Boyer1, David Devos2, Patrick Vourc'h1, Christian R Andres1, Philippe Corcia1.   

Abstract

BACKGROUND: Pathophysiological mechanisms that contribute to neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) include oxidative stress and inflammation. We conducted a preliminary study to explore these mechanisms, to discuss their link in ALS, and to determine the feasibility of incorporating this combined analysis into current biomarkers research.
METHODS: We enrolled 10 ALS patients and 10 controls. We measured the activities of glutathione peroxidase, glutathione reductase, superoxyde dismutase (SOD), and the levels of serum total antioxidant status (TAS), malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and glutathione status (e.g. glutathione disulfide, GSSG/reduced glutathione, GSH). We analysed the concentrations of homocysteine, several cytokines, vitamins and metals by standard methods used in routine practice.
RESULTS: There was a significant decrease in TAS levels (p=0.027) and increase in 8-OHdG (p=0.014) and MDA (p=0.011) levels in ALS patients. We also observed a significantly higher GSSG/GSH ratio (p=0.022), and IL-6 (p=0.0079) and IL-8 (p=0.009) concentrations in ALS patients. Correlations were found between biological and clinical markers (homosysteine vs. clinical status at diagnosis, p=0.02) and between some biological markers such as IL-6 vs. GSSG/GSH (p=0.045) or SOD activity (p=0.017).
CONCLUSION: We confirmed the systemic alteration of both the redox and the inflammation status in ALS patients, and we observed a link with some clinical parameters. These promising results encourage us to pursue this study with collection of combined oxidative stress and inflammatory markers.

Entities:  

Keywords:  ALS; biomarkers; homocysteine; neuroinflammation; oxidative stress; vitamin

Mesh:

Substances:

Year:  2016        PMID: 27774920     DOI: 10.1017/cjn.2016.284

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  29 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

2.  The transcription factor REST up-regulates tyrosine hydroxylase and antiapoptotic genes and protects dopaminergic neurons against manganese toxicity.

Authors:  Edward Pajarillo; Asha Rizor; Deok-Soo Son; Michael Aschner; Eunsook Lee
Journal:  J Biol Chem       Date:  2020-01-30       Impact factor: 5.157

3.  Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.

Authors:  Hiroshi Mitsumoto; Diana C Garofalo; Regina M Santella; Eric J Sorenson; Björn Oskarsson; J Americo M Fernandes; Howard Andrews; Jonathan Hupf; Madison Gilmore; Daragh Heitzman; Richard S Bedlack; Jonathan S Katz; Richard J Barohn; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Sharon P Nations; Andrea J Swenson; Pam Factor-Litvak
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-04-10       Impact factor: 4.092

Review 4.  Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?

Authors:  Benjamin Hall; Jonathan G George; Scott P Allen
Journal:  Histol Histopathol       Date:  2021-12-09       Impact factor: 2.303

5.  Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study.

Authors:  Yang Hu; Chang Cao; Xiao-Yan Qin; Yun Yu; Jing Yuan; Yu Zhao; Yong Cheng
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

6.  Expression of p16 and p21 in the frontal association cortex of ALS/MND brains suggests neuronal cell cycle dysregulation and astrocyte senescence in early stages of the disease.

Authors:  I Vazquez-Villaseñor; C J Garwood; P R Heath; J E Simpson; P G Ince; S B Wharton
Journal:  Neuropathol Appl Neurobiol       Date:  2019-06-17       Impact factor: 8.090

Review 7.  DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity.

Authors:  Jannigje Rachel Kok; Nelma M Palminha; Cleide Dos Santos Souza; Sherif F El-Khamisy; Laura Ferraiuolo
Journal:  Cell Mol Life Sci       Date:  2021-06-26       Impact factor: 9.261

8.  Perturbations of the Proteome and of Secreted Metabolites in Primary Astrocytes from the hSOD1(G93A) ALS Mouse Model.

Authors:  Roberto Stella; Raphael Severino Bonadio; Stefano Cagnin; Maria Lina Massimino; Alessandro Bertoli; Caterina Peggion
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

9.  Neuroprotective Effects of Genistein in a SOD1-G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Zichun Zhao; Jinsheng Fu; Shiping Li; Zhenzhong Li
Journal:  J Neuroimmune Pharmacol       Date:  2019-07-18       Impact factor: 4.147

10.  Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts.

Authors:  Margarita Gerou; Benjamin Hall; Ryan Woof; Jessica Allsop; Stephen J Kolb; Kathrin Meyer; Pamela J Shaw; Scott P Allen
Journal:  Neurobiol Aging       Date:  2021-04-27       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.